STUDresearch · Peptide
Ac-SDKP
Also known as
N-acetyl-Ser-Asp-Lys-Pro · AcSDKP · thymosin beta-4 metabolite
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ
Healing & repair
Endogenous peptide studied for systemic anti-fibrotic effects; organ-focused discussion does not establish local targeting or oral delivery.
What people say
A thymosin-β4 fragment discussed for anti-fibrotic and recovery research. Ac-SDKP is not the TB-500 fragment; organ-focused bioregulator marketing should not be mistaken for a proven locally targeted treatment.
Doses people talk about
The original notes provide no reliable public mg/day self-use chart. Human PK is a separate historical experiment and is not used here to create a consumer dose.
How it may feel
The notes retain recovery hopes, injection-site reactions and GI/mood concerns, but much of the timing language comes from broader peptide culture. The reviewed Ac-SDKP discussion offers no dependable first-person benefit-duration account.
Animal-model context1–1000 mcg/kg
Original model-specific literature band; route and frequency are not specified as one protocol. No animal-to-human equivalence.
Half-life & effect duration
- Half-life in the body
- After IV infusionAbout 4.5 minutes
- Felt duration people report
- Felt durationNo consistent Ac-SDKP-specific window reported
Cycles people discuss
10–20 day courses, seasonal repetition and weeks-on / weeks-off remain as bioregulator lore. Cost and caution drive the described breaks; no Ac-SDKP calendar is established, and adverse effects warrant reassessment.
Timing
The human IV elimination measurement is separate from course length, injection absorption and felt benefit. Training, sleep and side-effect timing remain practical discussion context—not evidence for a particular schedule.
Stacks
The existing notes mention multi-bioregulator combinations by organ system and solo comparisons. These are broader stack patterns; multiple agents make adverse effects and benefit attribution uncertain.
Watch for
Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
4.5 min after IV infusion in healthy volunteers.
Historical seraspenide study: mean elimination after infusion cessation, with 6 healthy volunteers. SubQ/IM peak timing and slower patient clearance are separate findings.
Small study; not gray-market equivalence, SubQ duration or anti-fibrotic benefit timing. Abstract review only.
- Ezan et al. 1994: NAc-SDKP pharmacokinetics in volunteers and chemotherapy patients (opens in a new tab)Abstract: six healthy volunteers, 12-hour IV infusion cessation, mean elimination half-life; separate SubQ/IM peak-time results and patient clearance comparison.Actual PubMed abstract reviewed; full article not available through this record. Small historical study of seraspenide, not gray-market product equivalence or subjective benefit duration.
Felt duration people report
Ac-SDKP felt duration not established in the reviewed discussion.
The actual thread concerns fragment identity, not an Ac-SDKP response log. Existing 1–2-week and 2–4-week checkpoints and 10–20-day courses are retained as broader discussion context.
Sparse accessible discussion does not prove nobody has used it. The IV plasma result is not a felt-duration substitute.
- TB-500: few tested compounds had the right peptide chain (opens in a new tab)OP’s fragment-identity discussion and lquinta reply distinguishing Ac-SDKP 1–4 from TB-500 17–23.Actual public thread and visible replies reviewed. Discussion of identity and proposed anti-inflammatory function, not an Ac-SDKP first-person response log. No personal-use duration established here.
What people say
- anti-fibrotic peptide fragment narrative: Community and regional literature frame benefits around anti-fibrotic peptide fragment function and “normalization” language. forum
- What is thinner: Large modern multi-center RCTs are often absent for the specific peptide brand story. forum
- Recovery narrative: Ac-SDKP is discussed for soft-tissue bounce-back, joint noise, or post-strain continuity. forum
- Local vs systemic mental model: Pin-site lore and whole-body recovery stories often mix. forum
- Time-course lore: The existing notes retain a 2–4 week checkpoint used in broader recovery/bioregulator discussions. The reviewed Ac-SDKP thread does not establish that as a common Ac-SDKP response time. forum
Doses people talk about
- Human self-dose culture: no reliable public mg/day chart. forum
- Community: almost no bodybuilding pin consensus for Ac-SDKP. forum
- Animal literature scale: papers use model-specific bands often in the 1–1000 mcg/kg class depending on experiment — not a consumer protocol. animal
- Framing: Endogenous N-acetyl-seryl-aspartyl-lysyl-proline studied mainly in lab models. trial
How it may feel
- Days 1–7, broader peptide context: The existing notes flag site reactions if injected and GI/mood shifts if oral. These are retained class-context cautions, not a verified Ac-SDKP oral route or a measured benefit timeline. forum
- Course lore: 10–20 day courses repeated a few times per year appear in the existing bioregulator-culture notes; they are not an Ac-SDKP-specific tested schedule. forum
- Day 1, practical context: Route, sting and GI effects are retained from the existing practical notes. They do not establish what most Ac-SDKP users notice or demonstrate a “miracle” effect. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: A self-log checkpoint retained in the existing notes, not a demonstrated Ac-SDKP onset or duration. forum
Cycles people discuss
- Broader course culture: Short on, long off and seasonal repetition are retained bioregulator-discussion patterns, not an established Ac-SDKP calendar. forum
- Weeks-on / weeks-off lore: The existing self-protocol notes describe breaks rather than indefinite daily use, driven by cost and caution more than hard science. Their frequency among Ac-SDKP users is not established here. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Short-peptide lore vs measurement: Rapid clearance was assumed in the existing notes, with course timing emphasized over plasma levels. A historical human IV study instead supplies a specific elimination measurement; course length still does not measure bodily half-life or felt duration. forumtrial
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Published PK: Mean elimination half-life was 4.5 min after a 12-hour IV infusion ended in 6 healthy volunteers. SubQ and IM plasma peaks at 0.26 and 0.28 h are absorption timings, not half-lives or felt onset. Patient clearance differed; this is not a gray-market dosing schedule. trial
More on what it is
- What it is: Ac-SDKP is endogenous N-acetyl-seryl-aspartyl-lysyl-proline, a thymosin-β4 fragment discussed for anti-fibrotic effects. The existing cytomedine/Khavinson-style catalog comparison describes bioregulator marketing culture, not proof that Ac-SDKP is one of those organ-targeted products. Human RCT evidence must be separated from that brand story. forumtrial
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Ac-SDKP, not proof it works for you. forum
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Multi-bioregulator stacks: Often combined by organ system in protocols. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Generally mild claims: Vendor literature often claims good tolerability — independent long-term data limited. forum
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.